Search
site map
IP Handbook Blog
Your source for expert commentary on IP management issues.
Go to the blog
About
MIHR
PIPRA
Fiocruz, Brazil
bioDevelopments- Institute
|
KEUSCH, Gerald T
Professor Jerry Keusch is Associate Provost and Associate Dean for Global Health at Boston University and Director of the university’s Global Health Initiative. He is a physician-scientist, whose career has focused on the study of infectious diseases of developing countries at the laboratory and field levels. He has received all three of the major recognition awards of the Infectious Diseases Society of America for this work, including the Squibb, Finland and Bristol Awards. Professor Keusch is a member of Institute of Medicine at the U.S. National Academies, where he serves on its Board on Global Health. He is also a member of the Roundtable on Science and Technology for Sustainability at the National Research Council and its Task Force on Linking Knowledge with Action for Sustainable Development, both at the U.S. National Academies.
Prior to joining Boston University Professor Keusch was the Associate Director for International Research and Director of the Fogarty International Center at the U.S. National Institutes of Health. During his tenure funding for global health research and capacity building dramatically increased. Among the innovations he initiated were explorations into the creative use of intellectual property rights deemed to NIH grantees to insure that developing countries could benefit from discovery funded by public resources. His work in this area, together with the Rockefeller Foundation, led to the formation of the Center for the Management of Intellectual Property in Health Research (MIHR). He served on the Founding Board of MIHR and has subsequently been Vice-Chair of the MIHR Board.
Abstract
Global Health: Lessons from Bayh-Dole
Abstract:
Public sector institutions help deliver public health goods. By extension, universities that receive public research funds must deliver a benefit to the public that goes beyond licensing a discovery to the private sector for development. In the United States, 25 years of experience with the Bayh-Dole Act, which governs the use of intellectual property (IP) derived from public research, offers both lessons and warnings for developing countries currently establishing their own IP systems. Bayh-Dole successfully created a large body of IP from publicly funded research. Absent a strong profit motive for the private sector, however, the Act has been much less successful at producing public goods for health. Current practice undervalues the “public benefit” aspect of the mandate, especially for the poor. Possible ways to address this mandate would be for public sector entities (and their academic partners in the biomedical sciences) to invest some of their earnings from licensing publicly funded discoveries into programs for neglected diseases of the poor. IP rights from public funded research could also be leveraged in negotiating licensing agreements with the private sector to address these neglected diseases. IP laws and institutions should be designed to encourage such sharing. The public and academic research sectors should also seek a new compact with the private sector aimed at reducing the burden of disease affecting the poor.
|